Form 4: Denis Burger Discloses Aptose Biosciences Share Changes

Denis R. Burger, former director of Aptose Biosciences Inc., reported transactions involving common shares and stock options on June 30, 2026.

Summary

• Denis R. Burger, formerly a director of Aptose Biosciences Inc., has filed a statement detailing changes in his beneficial ownership of company securities.
• The transactions occurred on June 30, 2026, and involved the disposal of common shares and the reporting of various stock options.
• Burger disposed of 70 common shares at a price of $1.72 per share, which was converted from a Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
• This disposal was part of a business arrangement agreement where a subsidiary of Hammi Pharmaceuticals Co. Ltd. acquired all outstanding shares of Aptose Biosciences at C$2.41 per share.
• The filing also lists several director stock options with varying exercise prices and grant dates, all of which were reported as disposed of on June 30, 2026, in connection with the acquisition.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on past transactions related to an acquisition and does not offer new strategic insights or financial performance data.

Positives

• The filing clearly outlines the disposition of securities as part of a pre-approved business arrangement, indicating transparency.
• The acquisition price of C$2.41 per share for all outstanding shares suggests a definitive exit for shareholders involved in the transaction.

Negatives

• The disposal of 70 common shares by a former director, even if part of a larger acquisition, represents a reduction in direct holdings.
• The complex nature of stock option reporting and adjustments due to reverse stock splits can obscure the precise value and impact for some stakeholders.

Risks

• The filing mentions reverse stock splits (1:30 on 2/26/25 and 1:15 on 6/6/2023), which can sometimes be a sign of a company struggling to maintain its stock price or meet exchange listing requirements.
• The acquisition by Hammi Pharmaceuticals Co. Ltd. introduces a change in control, the long-term implications of which for Aptose Biosciences' operations and strategy are not detailed in this filing.

Future Outlook

This filing primarily reports past transactions related to an acquisition and does not contain forward-looking statements or guidance from management regarding future business operations or financial performance.

Management Comments

• The filing notes that the disposal of securities was made pursuant to a board, shareholder, and court-approved business arrangement agreement with Hammi Pharmaceuticals Co. Ltd.
• It is also noted that total options and option exercise prices are subject to adjustment as a result of the issuer's reverse stock splits.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The context of an acquisition by a foreign entity (Hammi Pharmaceuticals) is a common strategic move in the biotechnology sector, often aimed at consolidating market position or accessing new technologies.

Management Changes

Stakeholder Impact

• Shareholders: Shareholders of Aptose Biosciences Inc. have had their shares acquired at C$2.41 per share as part of the business arrangement with Hammi Pharmaceuticals Co. Ltd.
• Management/Employees: Denis R. Burger, a former director, has completed his transactions related to the acquisition. Other employees' situations are not detailed in this filing.
• Creditors: The impact on creditors is not specified in this filing, but an acquisition typically involves the assumption of liabilities by the acquiring entity.

Next Steps

• The acquisition by Hammi Pharmaceuticals Co. Ltd. is the primary event described, implying a transition of ownership and control.
• Further filings from Aptose Biosciences or Hammi Pharmaceuticals may provide details on the integration of the companies or future strategic directions.

Key Dates

Keywords

Form 4, SEC Filing, Aptose Biosciences, Denis R. Burger, Stock Options, Beneficial Ownership, Insider Trading, Acquisition, Hammi Pharmaceuticals, Director Stock Option, Common Shares, Reverse Stock Split